Movement Alert｜SKB BIO Rises 3.25% in Regular Trading, H1 Swing to Profit with Net Income Reaching 388 Million Yuan

Market Focus

Aug 18

On August 18, SKB BIO rose 3.25% in regular trading, trading at 540.0 HKD/share, with turnover of HKD 143 million. The move was driven by the company's interim results released on August 17, which showed a significant turnaround from loss to profit.

According to the filing, SKB BIO reported H1 revenue of 978.3 million yuan, up 2.9% year-over-year, with gross profit of 737 million yuan, up 11.7%. Net profit attributable to shareholders reached 388 million yuan, compared with a loss of 145.2 million yuan in the year-ago period, representing a full swing to profitability. Earnings per share stood at 1.6639 yuan versus a prior-year loss per share of 0.6371 yuan.

The performance improvement was primarily attributed to the company's strategic transition from an R&D-focused biotech to a full-chain biopharma. Its core product, TROP2 ADC sacituzumab tirumotecan, has now received approval for four indications in China, with multiple registrational clinical studies continuing to advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1159970324"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159970324\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159970324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 11:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159970324","market":"hk","top_or_hot":-1,"title":"Movement Alert｜SKB BIO Rises 3.25% in Regular Trading, H1 Swing to Profit with Net Income Reaching 388 Million Yuan","media":"Market Focus","content":"<p><p>On August 18, SKB BIO rose 3.25% in regular trading, trading at 540.0 HKD/share, with turnover of HKD 143 million. The move was driven by the company's interim results released on August 17, which showed a significant turnaround from loss to profit.</p><p>According to the filing, SKB BIO reported H1 revenue of 978.3 million yuan, up 2.9% year-over-year, with gross profit of 737 million yuan, up 11.7%. Net profit attributable to shareholders reached 388 million yuan, compared with a loss of 145.2 million yuan in the year-ago period, representing a full swing to profitability. Earnings per share stood at 1.6639 yuan versus a prior-year loss per share of 0.6371 yuan.</p><p>The performance improvement was primarily attributed to the company's strategic transition from an R&D-focused biotech to a full-chain biopharma. Its core product, TROP2 ADC sacituzumab tirumotecan, has now received approval for four indications in China, with multiple registrational clinical studies continuing to advance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SKB BIO Rises 3.25% in Regular Trading, H1 Swing to Profit with Net Income Reaching 388 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SKB BIO Rises 3.25% in Regular Trading, H1 Swing to Profit with Net Income Reaching 388 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-18 11:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 18, SKB BIO rose 3.25% in regular trading, trading at 540.0 HKD/share, with turnover of HKD 143 million. The move was driven by the company's interim results released on August 17, which showed a significant turnaround from loss to profit.</p><p>According to the filing, SKB BIO reported H1 revenue of 978.3 million yuan, up 2.9% year-over-year, with gross profit of 737 million yuan, up 11.7%. Net profit attributable to shareholders reached 388 million yuan, compared with a loss of 145.2 million yuan in the year-ago period, representing a full swing to profitability. Earnings per share stood at 1.6639 yuan versus a prior-year loss per share of 0.6371 yuan.</p><p>The performance improvement was primarily attributed to the company's strategic transition from an R&D-focused biotech to a full-chain biopharma. Its core product, TROP2 ADC sacituzumab tirumotecan, has now received approval for four indications in China, with multiple registrational clinical studies continuing to advance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1159970324","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159970324","pubTimestamp":1787024511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 18, SKB BIO rose 3.25% in regular trading, trading at 540.0 HKD/share, with turnover of HKD 143 million. The move was driven by the company's interim results released on August 17, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势提醒|SKB生物常规交易上涨3.25%，上半年扭亏为盈，净利润达3.88亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On August 18, SKB BIO rose 3.25% in regular trading, trading at 540.0 HKD/share, with turnover of HKD 143 million. The move was driven by the company's interim results released on August 17, which showed a significant turnaround from loss to profit.According to the filing, SKB BIO reported H1 revenue of 978.3 million yuan, up 2.9% year-over-year, with gross profit of 737 million yuan, up 11.7%. Net profit attributable to shareholders reached 388 million yuan, compared with a loss of 145.2 million yuan in the year-ago period, representing a full swing to profitability. Earnings per share stood at 1.6639 yuan versus a prior-year loss per share of 0.6371 yuan.The performance improvement was primarily attributed to the company's strategic transition from an R&D-focused biotech to a full-chain biopharma. Its core product, TROP2 ADC sacituzumab tirumotecan, has now received approval for four indications in China, with multiple registrational clinical studies continuing to advance.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}